5 Gastroenterology Headlines You Missed in February 2026 (HCP Live)

February 2026 was defined by durability data and real-world insight across inflammatory bowel disease (IBD), with multiple long-term analyses presented at the 21st Congress of European Crohn’s and Colitis Congress (ECCO). Extended findings from the LUCENT clinical program reinforced sustained efficacy and safety of mirikizumab in ulcerative colitis (UC) through 4 years of continuous therapy, strengthening its position as a potential disease-modifying option. Complementing this, head-to-head SEQUENCE data continued to shape treatment sequencing decisions in Crohn’s disease, particularly for patients with prior anti-TNF exposure, while interim results from the real-world PROFUNDUS study helped clarify how upadacitinib performs outside the constraints of randomized trials.